Citations

Showing 10 of 108152 citations.

Aducanumab: What about the Patient?
Petersen, Ronald C.

Mayo Clinic

Annals of Neurology | July 28, 2021 | Volume: 90 | Issue: 3 | Pages: 334-335

10.1002/ana.26181 | PMID 34322904 Get It

In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications
Bates, Emily A. , Counsell, John R. , Alizert, Sophie, Suff, Natalie , Boyle, Ashley K. , Bradshaw, Angela C., Waddington, Simon N. , Nicklin, Stuart A. , Baker, Andrew H. , Parker, Alan L. , Bradshaw, Angela C. , Baker, Alexander T. , Suff, Natalie , Boyle, Ashley , Waddington, Simon N , Nicklin, Stuart A , Baker, Andrew H , Parker, Alan L , Bates, Emily

Mayo Clinic

Viruses | July 28, 2021 | Volume: 13 | Issue: 8 | Pages: 1483

10.3390/v13081483 | PMID 34452348 Get It

The human adenovirus phylogenetic tree is split across seven species (A–G). Species D adenoviruses offer potential advantages for gene therapy applications, with low rates of pre-existing immunity detected across screened populations. However, many aspects of the basic virology of species D—such as their cellular tropism, receptor usage, and in vivo biodistribution profile—remain unknown. Here, we have characterized human adenovirus type 49 (HAdV-D49)—a relatively understudied species D member. We report that HAdV-D49 does not appear to use a single pathway to gain cell entry, but appears able to interact with various surface molecules for entry. As such, HAdV-D49 can transduce a broad range of cell types in vitro, with variable engagement of blood coagulation FX. Interestingly, when comparing in vivo biodistribution to adenovirus type 5, HAdV-D49 vectors show reduced liver targeting, whilst maintaining transduction of lung and spleen. Overall, this presents HAdV-D49 as a robust viral vector platform for ex vivo manipulation of human cells, and for in vivo applications where the therapeutic goal is to target the lung or gain access to immune cells in the spleen, whilst avoiding liver interactions, such as intravascular vaccine applications.
Revisiting FDA Approval of Aducanumab
Emerson, Scott S. , Ovbiagele, Bruce , Kryscio, Richard J. , Perlmutter, Joel S. , Kesselheim, Aaron S, Alexander, G. Caleb , Knopman, David S. , Ovbiagele, Bruce , Kesselheim, Aaron Seth

Mayo Clinic

New England Journal of Medicine | July 28, 2021 | Volume: 385 | Issue: 9 | Pages: 769-771

10.1056/nejmp2110468 | PMID 34320282 Get It

FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Gile, Jennifer , Ou, Fang‐Shu , Mahipal, Amit , Larson, Joseph J. , Mody, Kabir , Jin, Zhaohui , Hubbard, Joleen M. , Hálfdánarson, Þorvarður R. , Alberts, Steven R. , Jatoi, Aminah , Smoot, Rory L. , Roberts, Lewis R. , Bekaii‐Saab, Tanios , Gile, Jennifer Jane , Hubbard, Joleen , Halfdanarson, Thorvardur R , McWilliams, Robert R , Ma, Wen Wee , Ilyas, Sumera, Roberts, Lewis R , Borad, Mitesh J , Smoot, Rory L , Mahipal, Amit , Alberts, Steven R , Ou, Fang-Shu , Bekaii-Saab, Tanios S , Jin, Zhaohui , McWilliams, Robert R. , Wee, Wen , Ilyas, Sumera I. , Gores, Gregory J. , Borad, Mitesh J. , Tran, Nguyen H.

Mayo Clinic

JCO Precision Oncology | July 28, 2021 | Volume: No volume available | Issue: 5 | Pages: 1228-1240

10.1200/po.21.00064 | PMID 34778691 Get It

PURPOSECholangiocarcinomas (CCA) are a group of heterogeneous tumors arising from the biliary epithelia. Significant sequencing efforts have provided further insights into the molecular mechanisms of this disease including fibroblast growth factor receptor ( FGFR) alterations, which occurs in approximately 15%-20% of intrahepatic CCAs. Herein, we describe the FGFR inhibitor (FGFRi)-associated treatment toxicity and cancer-specific outcomes from a multicenter single-institution cohort.METHODSThis is a retrospective study of patients with CCA and known FGFR alterations treated with FGFRi. We describe the toxicity and efficacy in patients treated at Mayo Clinic between January 2010 and December 2020.RESULTSOur group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFR alterations who received FGFRi. The most common grade 1 or higher adverse events for all patients included fatigue (92%), AST elevations (78%), anemia (80%), decreased platelet count (63%), and hyperphosphatemia (74%). Median progression-free survival on FGFRi was 5.8 months for all patients (95% CI, 4.9 to 9.0). Females had significantly longer progression-free survival at 6.9 months (95% CI, 5.2 to 11.8) on FGFRi compared with males at 4.9 months (95% CI, 2.8 to not estimable; P = .038).CONCLUSIONFGFRi are well tolerated with clinical efficacy. With the recent approval of FGFRi by the US Food and Drug Administration and ongoing clinical trials for new FGFRi, understanding outcomes and toxicity associated with these medications is important for precision oncology.
Clinical manifestation, management and prognosis of clear cell meningioma: an evidence-based review
Dutta, Priyata , Agarwala, Preeti, Ikram, Samar, Ahsan, Eram, Shourav, Md Manjurul Islam , Riviere-Cazaux, Cécile , Abuleil, Amro, Bhorkar, Aprajita Milind, Reza, Rezaur Rahman, Siddik, Abu Bakar , Rahman, Masum , Siddik, Abu Bakar , Shourav, Md Manjurul Islam

Mayo Clinic

International Journal of Neuroscience | July 28, 2021 | Volume: 133 | Issue: 6 | Pages: 648-653

10.1080/00207454.2021.1956919 | PMID 34319820 Get It

A Retrospective Examination of the Impact of Pharmacotherapy on Parent–Child Interaction Therapy
Wang, Chris , Hu, Yuliang , Nakonezny, Paul A. , Melo, Valéria , Ale, Chelsea M. , Athreya, Arjun P. , Shekunov, Julia , Lynch, Rachel L., Croarkin, Paul E. , Romanowicz, Magdalena , Ale, Chelsea, Lynch, Rachel, Croarkin, Paul E

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | July 28, 2021 | Volume: 31 | Issue: 10 | Pages: 685-691

10.1089/cap.2021.0043 | PMID 34319785 Get It

Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS
Coyne, Alyssa N. , Baskerville, Victoria, Zaepfel, Benjamin L. , Dickson, Dennis W. , Rigo, Frank , Bennett, Frank , Lusk, C. Patrick , Rothstein, Jeffrey D. , Dickson, Dennis W , Coyne, Alyssa N , Rothstein, Jeffrey D

Mayo Clinic

Science Translational Medicine | July 28, 2021 | Volume: 13 | Issue: 604 | Pages: No page available

10.1126/scitranslmed.abe1923 | PMID 34321318 Get It

Nuclear accumulation of CHMP7 leads to multiple cellular pathologies that can be mitigated via CHMP7 ASOs in familial and sporadic ALS iPSNs.
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Auclair, Daniel , Adam, Stacey J. , Agarwal, Amit , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica R. , Connors, Dana E. , Dash, Ajeeta B. , Bacco, Alessandra Di , Ling, Du, Flores‐Montero, Juan , Ghobrial, Irene M. , Gormley, Nicole , Gupta, Ira, Higley, Howard R., Hillengaß, Jens , Kanapuru, Bindu , Kazandjian, Dickran , Kelloff, Gary J. , Kremer, Brandon E. , Lightbody, Elizabeth D. , Lomas, Oliver , Mateos, María‐Victoria , de, Rocío Montes , Mukundan, Lata , Munshi, Nikhil C. , O’Donnell, Elizabeth , Paiva, Bruno , Patel, Reshma, Pugh, Trevor J. , Ramasamy, Karthik , Ray, Jill, Roshal, Mikhail , Ross, Jeremy A. , Sigman, Caroline C. , Thoren, Katie , Trudel, Suzanne , Ulaner, Gary A. , Valente, Nancy, Weiss, Brendan M. , Zamagni, Elena , Kumar, Shaji , Adam, Stacey J , Anderson, Melissa , Bustoros, Mark , Chapman, Jessica , Connors, Dana E , Dash, Ajeeta B , Di Bacco, Alessandra , Flores-Montero, Juan , Gay, Francesca , Hillengass, Jens , Landgren, C Ola , Lomas, Oliver C , Montes de Oca, Rocio , Pugh, Trevor J , Ramasamy, Karthik , Sigman, Caroline C , Thoren, Katie L , Paiva, Bruno , Ghobrial, Irene M , Ulaner, Gary , Gormley, Nicole , Anderson, Kenneth C. , Avet‐Loiseau, Hervé , Facon, Thierry T.F. , Gay, Francesca , Kirsch, Ilan R. , Landgren, Ola , Lonial, Sagar , Órfão, Alberto , Patel, Reshma, Zamagni, Elena

Mayo Clinic

Clinical Cancer Research | July 28, 2021 | Volume: 27 | Issue: 19 | Pages: 5195-5212

10.1158/1078-0432.ccr-21-1059 | PMID 34321279 Get It

AbstractThe development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes.
Two waves of coeliac disease incidence in Sweden: a nationwide population-based cohort study from 1990 to 2015
Bergman, David , King, James A. , Lebwohl, Benjamin , Clements, Mark , Roelstraete, Björn , Green, Peter Hr, Murray, Joseph A. , King, James , Kaplan, Gilaad G , Murray, J A , Kaplan, Gilaad G. , Ludvigsson, Jonas F.

Mayo Clinic

Gut | July 28, 2021 | Volume: 71 | Issue: 6 | Pages: 1088-1094

10.1136/gutjnl-2021-324209 | PMID 34321220 Get It

Objectives To assess the incidence of biopsy-verified coeliac disease (CD) in Sweden and examine the incidence of duodenal/jejunal biopsies with normal mucosa over time as a proxy for CD awareness and investigation. Design Nationwide population-based cohort study 1990–2015 based on biopsy reports indicating villous atrophy (VA) or normal mucosa in the duodenum/jejunum. Results We identified 44 771 individuals (63% females) with a biopsy report specifying VA and 412 279 (62% females) with a biopsy report indicating normal mucosa (without a prior biopsy indicating VA). The median age at diagnosis of CD was 28 years. The mean age-standardised incidence rate during the study period was 19.0 per 100 000 person-years (95% CI 17.3 to 20.8). The incidence reached a peak in 1994 for both sexes and a second higher peak in 2002–2003 for females and in 2006 for males. The lifetime risk of developing CD was 1.8% (2.3% in females and 1.4% in males). Prior to 2015, there was a parallel rise in rates for biopsies showing normal duodenal/jejunal mucosa. Conclusions In Sweden, the incidence of CD increased until 2002–2003 in females and until 2006 in males. Since then, the incidence of CD has declined despite increasing duodenal/jejunal biopsies, suggesting that increased awareness and investigation are unlikely to elevate the incidence of the disease in Sweden. Across a lifetime, 1 in 44 females and 1 in 72 males are expected to be diagnosed with CD in Sweden, indicating a relatively high societal burden of disease.